149 Lifestyle, Blood Pressure, Lipids and Diabetes Management in Patients with Coronary Heart Disease From 24 Countries in Europe

Abstract

Introduction EUROASPIRE surveys, conducted by the European Society of Cardiology in 1995-96 (9 countries), 1999-2000 (15 countries) and 2006-2007 (22 countries) showed a high prevalence of modifiable risk factors in patients with coronary heart disease (CHD) in Europe and a real potential to further reduce morbidity and mortality. The aim of the EUROASPIRE IV survey was to determine in patients with CHD whether the Joint European Societies’ guidelines on cardiovascular disease (CVD) prevention are being followed in clinical practice. Methods EUROASPIRE IV survey was undertaken in 74 centres in 24 European countries. Consecutive patients, men and women Results A total of 16,426 medical records (24.4% females) were reviewed and 7,998 patients were interviewed on average 1.4 years following their index event. At interview, 16.0% of patients smoked cigarettes, 37.6% were obese (BMI ≥ 30 kg/m2), 52.7% had central obesity (waist circumference ≥ 102 cm in men or ≥ 88 cm in women), 58.2% had raised blood pressure (BP ≥ 140/90 mmHg; ≥ 140/80 mmHg for patients with diabetes), 80.5%% had LDL cholesterol ≥ 1.8 mmol/l and 26.8% had self-reported diabetes. The use of prophylactic drug therapies was as follows: aspirin or other anti-platelets drugs 93.8%, beta-blockers 82.6%, ACE inhibitors/ARBs 75.1%, and statins 85.7%. Only 53.3% of patients using blood pressure lowering medication were controlled (BP Conclusions EUROASPIRE IV shows that a large majority of coronary patients have adverse lifestyles and many do not achieve the blood pressure, lipid and diabetes targets. A wide gap continues to exist in the implementation of evidence-based medicine in cardiological practice in both hospital and primary care. There is a considerable potential to raise the standard of preventive care in Europe through preventive cardiology programmes involving multidisciplinary teams of health-care professionals helping patients to achieve the lifestyle, risk factors and therapeutic targets for CVD prevention.